Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04873050 · ClinicalTrials.gov registry record · Phase 4
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
A Phase 4 study of Pre Diabetes and Postpartum Disorder, sponsored by Woman's.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 102
- Enrollment target
- 1
- Study location
NCT04873050 is a Phase 4 study of Pre Diabetes and Postpartum Disorder that is actively recruiting participants, run by Woman's. The registered enrollment target is 102 participants, below the 728-participant average among 59 other Pre Diabetes trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04873050, a Phase 4 study of Pre Diabetes and Postpartum Disorder, is actively recruiting participants, sponsored by Woman's.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 102 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia; thereby filling a gap in efficacious pharmacologic intervention options for clinicians to support postpartum diabetes recovery and reduce future risk of T2DM in young women.
Conditions Studied
Interventions
- DRUG Semaglutide Pen Injector [Ozempic]
- DRUG Placebo semaglutide pen injector
Study Locations (1)
Louisiana
- Woman's Hospital - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04873050
The ClinicalTrials.gov registry entry for NCT04873050 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 59 other Pre Diabetes trials with a reported enrollment target (86% lower). The listed sponsor is Woman's, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pre Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Semaglutide Pen Injector [Ozempic] is the first listed.
NCT04873050 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT04873050 about?
NCT04873050 is a clinical study titled "Treatment to Regress to Normoglycemia in Women with a Recent History of GDM". The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia; thereby filling a gap in efficacious pharmacologic intervention options for clinicians to support postpartum diabete...
What is the current status of trial NCT04873050?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 102 participants. The study started on 2022-01-13. Estimated completion is 2026-03-01.
What conditions does trial NCT04873050 study?
This clinical trial studies the following conditions: Pre Diabetes, Postpartum Disorder.
What interventions are being tested in trial NCT04873050?
The interventions under investigation include: Semaglutide Pen Injector [Ozempic] (DRUG), Placebo semaglutide pen injector (DRUG).
Who is sponsoring clinical trial NCT04873050?
This trial is sponsored by Woman's, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04873050 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pre Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Incretins in Impaired Fasting Glucose
COMPLETED · Phase 4
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Optimizing Mango's Glycemic Impact: Investigating Mango Consumption Timing in Prediabetic Individuals
RECRUITING · NA
-
Glycemic Metrics and Patterns in People With and Without Prediabetes
RECRUITING
-
MegaNatural BP® GSE on Blood Pressure and Cardiometabolic Risk Factors
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.